Frequently asked questions

Kineret Q&A

How is Kineret administered?
  • Kineret is supplied in a pre-filled syringe containing 100 mg of anakinra per 0.67 ml (150 mg/ml).1
  • Kineret is administered as a subcutaneous injection.1
  • Dosage depends on the indication. In children, the dose is determined depending on body weight. Please refer to current SmPC.
How should Kineret be stored?
  • Kineret should be stored in a refrigerator between 2°C and 8°C.1
  • Kineret should not be frozen or shaken.1
  • Kineret should be kept in its original carton and away from light.1
  • Kineret may be kept at room temperature up to 25 °C for a maximum of 72 hours. After removal from the refrigerator, Kineret must be used within 72 hours or discarded. Once stored at room temperature, Kineret should not be placed back in the refrigerator.
How can injection site reactions be managed?

Injection site reactions (ISRs) are common and typically mild to moderate. To alleviate symptoms, the following measures are recommended:

  • Alternate the injection site.
  • Cool the injection site with cold packs before and after administration.
  • Warm the injection liquid to room temperature before use.
  • Apply topical glucocorticoids or antihistamines after the injection if needed.

These strategies can help reduce discomfort and improve tolerability.

Can kineret be administered by IV?

No, the approved route of administration is subcutaneous injection

Can I treat my FMF patient with Kineret only during attacks?

Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). The SmPC does not support intermittent or on-demand use. Discontinuation of Kineret may lead to disease flares.

Can a patient with Hepatitis B be treated with Kineret?

Kineret is not contraindicated in patients with hepatitis B. However, other anti-rheumatic therapies have been associated with hepatitis B reactivation. Therefore, screening for viral hepatitis should be performed prior to initiating therapy, in accordance with published medical guidelines.

Is there a pediatric dose (syringes) in plan, like smaller doses to avoid waste?

The Summary of Product Characteristics does not cover future product developments, therefore no information is able to be provided.

For how long should a Stills patient be treated with Kineret before tapering begins?

Details on treatment duration and tapering are unavailable

How should the treatment with Kineret be tapered for a patient with Still´s disease?

Guidance on tapering treatment is not included in the Summary of Product Characteristics, therefore no guidance can be provided.

Can it be dosed with a JAK inhibitor?

Information on combination dosing is not available in the Summary of Product Characteristics, therefore guidance cannot be provided.